Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii

Payandeh, Zahra; Rasooli, Iraj; Gargari, Seyed Latif Mousavi; Bazl, Masoumeh Rajabi; Ebrahimizadeh, Walead

doi:10.1093/trstmh/trt114

Cited by 26 publications

(18 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Better cut off value in the ELASA system for A. baumannii could be due to the development of higher affinity aptamers (7.547 ± 1.353 pM) and nanobody (3.8 × 10 -8 M/L). Whereas in the present work, the Kd for aptamer and VHH were 15.404 ± 4.776 pM and 5 × 10 -8 M, respectively (30). For detection of OmpW and CtxB antigens of V. cholerae, Tuteja et al developed a dip-stick sandwich ELISA where the analytical sensitivity of the designed assay was 60 pg/ml for CtxB and 10 4 CFU•ml -1 for OmpW (31).…”

Section: Discussionmentioning

confidence: 49%

Aptamer-nanobody based ELASA for detection of Vibrio cholerae O1

Mojarad¹,

Gargaria²

2020

IJM

View full text Add to dashboard Cite

Background and Objectives: In recent years, the prevalence of diseases caused by Vibrio spp. is increasing in the world, and among them species, Vibrio cholerae is the most important Vibrio associated with pandemic and epidemic cholera outbreaks. Therefore, the development of a reliable method for early and accurate detection of V. cholerae for management of diseases is a real need. Aptamers with the ability to detect targets with high specificity and accuracy can be one of the candidates used for the whole cell and thereby V. cholerae detection. Materials and Methods: In this research high-affinity DNA aptamers against with two major serotypes of Inaba (ATCC 39315) and Ogawa (clinical sample) were selected from DNA aptamer library through 12 rounds of Systematic Evolution of Ligands by Exponential (SELEX) enrichment procedure using live cells as a target which monitored with flow cytometry. Results: The binding efficiency and dissociation constant of the isolated aptamers V.ch47 and V.ch27 were 56.4%, 53.3% and 15.404 ± 4.776 pM, 20.186 ± 3.655 pM, respectively. A sandwich Enzyme-linked aptamer sorbent assay (ELASA) was developed with the biotinylated V.ch47 aptamer and our previously developed nanobody anti-Lipopolysaccharides (LPS). We optimized this system with V. cholerae O1 and analyzed their cross reactivity with close physiological bacteria. The threshold of detection was obtained 104 CFU/ml in the sandwich ELASA process. Conclusion: Our results showed that the sandwich ELASA is sensitive enough for the rapid detection of V. cholerae from other bacteria.

show abstract

Section: Discussionmentioning

confidence: 49%

Aptamer-nanobody based ELASA for detection of Vibrio cholerae O1

Mojarad¹,

Gargaria²

2020

IJM

View full text Add to dashboard Cite

show abstract

“…Since then, two other anti-CD20 T A B L E 2 Amino acid sequences of signal peptides as well as heavy and light chains of anti-CD20 antibodies | 945 mAb were granted EMA approval for CLL. 6 Mechanisms of action of anti-CD20 mAb, which induce tumor cell death, is antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity (CDC), and direct cellular cytotoxicity (DC). Single-agent activity of rituximab is limited in B-cell malignancy.…”

Section: Discussionmentioning

confidence: 99%

Affinity maturation and characterization of the ofatumumab monoclonal antibody

Payandeh

Rajabibazl

Mortazavi

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

CD20 molecule, a phosphoprotein with 297 amino acids and four transmembrane domains, is a member of MS4A protein family. Anti-CD20 antibodies such as ofatumumab, which have been developed for cancer treatment and has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. Rational engineering methods can be applied with reasonable success to improve functional characteristics of antibodies. Considering the importance of this issue, we have used in silico modeling approach for the improvement of ofatumumab monoclonal antibody. Four mutated variants of ofatumumab were developed and expressed in Chinese hamster ovary (CHO) cells along with the unmodified antibody. Analysis of affinity of the purified antibodies with CD20 showed significant improvement in antigen-binding characteristics of one of the variants compared with the control antibody. This study represents the first step toward development of the second generation ofatumumab antibody with improved affinity.

show abstract

“…The performance of nanobodies is based on their robust,size and architecture, which is combined with the characteristic variance in the length of CDR3 [ 88 , 89 ]. Nanobodies are typically generated by naïve, immune, and synthetic libraries.…”

Section: Generation Mechanism Of Antibodies Nanobodies and Bi-specific Antibodiesmentioning

confidence: 99%

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a universal heterogeneous disease that is characterized by genetic and epigenetic alterations. Immunotherapy using monoclonal antibodies (mAb) and cancer vaccines are substitute strategies for CRC treatment. When cancer immunotherapy is combined with chemotherapy, surgery, and radiotherapy, the CRC treatment would become excessively efficient. One of the compelling immunotherapy approaches to increase the efficiency of CRC therapy is the deployment of therapeutic mAbs, nanobodies, bi-specific antibodies and cancer vaccines, which improve clinical outcomes in patients. Also, among the possible therapeutic approaches for CRC patients, gene vaccines in combination with antibodies are recently introduced as a new perspective. Here, we aimed to present the current progress in CRC immunotherapy, especially using Bi-specific antibodies and dendritic cells mRNA vaccines. For this aim, all data were extracted from Google Scholar, PubMed, Scopus, and Elsevier, using keywords cancer vaccines; CRC immunotherapy and CRC mRNA vaccines. About 97 articles were selected and investigated completely based on the latest developments and novelties on bi-specific antibodies, mRNA vaccines, nanobodies, and MGD007.

show abstract

Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii

Cited by 26 publications

References 24 publications

Aptamer-nanobody based ELASA for detection of Vibrio cholerae O1

Aptamer-nanobody based ELASA for detection of Vibrio cholerae O1

Affinity maturation and characterization of the ofatumumab monoclonal antibody

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

Contact Info

Product

Resources

About